Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-765 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| VX-765 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-765 | DRUG | 300mg Oral Tablet, 900mg TID |
Inclusion Criteria: * Subjects that are male or female aged 18 to 64 years (inclusive) with a body mass index between 18 and 35 (kg/m2) * Subjects must have a diagnosis and history of treatment resistant partial onset seizures for which they are taking 1 to 4 concomitant antiepileptic drugs (AED). ...
VX-765 is an investigational small molecule being developed by Vertex Pharmaceuticals (VRTX) for partial epilepsy and psoriasis. It is in Phase 2 clinical development. VX-765 has been studied in completed Phase 2 trials for both conditions, but it is not approved and remains investigational.
VX-765 is being studied for use in partial epilepsy and psoriasis. In partial epilepsy, it was evaluated in patients with treatment-resistant disease. In psoriasis, it was studied as an oral investigational drug. Both indications are in Phase 2 clinical development.
VX-765 is being developed by Vertex Pharmaceuticals Incorporated, which trades on the stock exchange under the ticker VRTX. Vertex is the developer of this investigational small molecule for partial epilepsy and psoriasis.
VX-765 is in Phase 2 clinical development. It has completed Phase 2 trials for both partial epilepsy and psoriasis. VX-765 is not FDA approved and remains an investigational drug in clinical development.
VX-765 has been studied in two completed Phase 2 trials. NCT00205465 evaluated VX-765 in 64 patients with psoriasis. NCT01048255 studied VX-765 in 60 patients with treatment-resistant partial epilepsy in the United States. Both trials are completed.
VX-765 is not known to have alternative names. It is an investigational small molecule developed by Vertex Pharmaceuticals for partial epilepsy and psoriasis. No other names for VX-765 have been reported.